

unisantė

Centre universitaire de médecine générale et santé publique · Lausanne



What is common between sweets, buildings and sunscreens? On the risk assessment and regulation of chemicals in Europe

Prof. Guseva Canu

Unisanté, Department of Occupational and Environnemental Health



Physical properties of TiO₂

- White inorganic compound
- Occurs naturally as a solid
- Insoluble in water, even in its particle form
- Extremely high melting point of 1,843°C and boiling point of 2,972°C
- Refractive index (ability to scatter UV light) very high >>> diamond
- Photocatalytic activity under UV light

=> Resistant, extra-white, bright, protective, aesthetic, very promising

https://tdma.info/uses-of-titanium-dioxide/ https://www.youtube.com/watch?v=7ObnoGtDi0Q&t=93s/



What is titanium dioxide?



- White inorganic compound
- As a white pigment, TiO₂ is one of the most important raw materials for paints and coatings
- As a <u>photocatalyst</u>, titanium dioxide can be added to paints, cements, windows and tiles in order to <u>decompose environmental pollutants</u>.
- Beyond paints, catalytic coatings, plastics, paper, pharmaceuticals and sunscreen, some <u>lesser-known applications include packaging</u>, <u>commercial printing inks, cosmetics, toothpastes, and food</u> (E171)

What do we know regarding TiO₂ safety ?

Environ 8 110 000 résultats (0,73 secondes)

Titanium dioxide (TiO₂) is considered as an inert and **safe** material and has been used in many applications **for** decades. ... Although TiO₂ is permitted as an additive (E171) in food and pharmaceutical products **we do** not have reliable data **on** its absorption, distribution, excretion and toxicity **on** oral exposure.


https://www.ncbi.nlm.nih.gov > articles > PMC3423755

Titanium dioxide in our everyday life; is it safe? - NCBI - NIH Conclusions

Until relevant toxicological and human exposure data that would enable reliable risk assessment are obtained, TiO₂ nanoparticles should be used with great care. Radiol Oncol. 2011 Dec; 45(4): 227–247. Published online 2011 Nov 16. doi: 10.2478/v10019-011-0037-0

What do we know regarding TiO₂ safety ?

• Currently available Occupational Exposure Limits (OEL) in $\mu g/m3$




- Total dust Ultrafine TiO2 (respiratory fraction)
- Fine TiO2 (respiratory fraction) Nano-TiO2
- ENM such as TiO2 ■ TiO2 (respiratory fraction)

- Biopersistent ENM such as TiO2 (density 1)
- Biopersistent ENM such as TiO2 (density 2.5)
- Aglomerated biopersistent ENM with no specific toxicity (density 1.5-2.5)
- Ultrafine TiO2
 - ENM of low solubility such as ultrafine TiO2 Biopersistent dust such as TiO2 (respiratory fraction, density 1)


Abbreviations: REL, recommended exposure limit; PEL, permissible exposure limit; BEL, benchmark exposure level; OEL^a, OEL for cancer risk 1/5000; OEL^b, OEL for cancer risk 1/2000 ; OEL^c, regulatory OEL, OEL PL^d, 15y period limited OEL; ENM, engineered nanomaterials

NIOSH framework of Risk Assessment & Risk Management




Decision-making

WHO risk analysis framework




US NRC Risk Assessment/Risk Management framework



Hazard identification

- Slowly soluble particles not otherwise regulated or classified (TWA of total suspended particles or dusts)
- Case report Yamadori *et al.* (1986) reported a papillary adenocarcinoma of the lung and titanium dioxide-associated pneumoconiosis in a male titanium dioxide packer with 13 years of potential dust exposure and a 40-year history of tobacco smoking.
- 1st assessment IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 47 (IARC, 1989) => Not classifiable as to its carcinogenicity to humans (group 3)



ESLC: Evidence suggesting lack of carcinogenicity

IARC evaluation Framework for human data	Cancer in humans — Preamble Part B, Section 6(a)	Cancer in experimental animals					
	Sufficient evidence	Causal relationship has been <u>established</u> Chance, bias, and confounding <u>could be ruled out with</u> <u>reasonable confidence</u>					
	Limited evidence	Causal interpretation is <u>credible</u> Chance, bias, or confounding <u>could not be ruled out</u>					
	Inadequate evidence	Studies permit no conclusion about a causal association					
	Evidence suggesting lack of carcinogenicity	Several adequate studies covering the full range of exposure levels are mutually consistent in not showing a positive association at any observed level of exposure Conclusion is limited to cancer sites and conditions studied					

Hazard identification

- 2nd assessment in <u>2006</u> Volume 93 (IARC, 2010) => Possibly carcinogenic to humans (Group 2B)
 - There is *inadequate evidence* in humans for the carcinogenicity of titanium dioxide.
 - There is *sufficient evidence* in experimental animals for the carcinogenicity of titanium dioxide

Human carcinogenicity data


- Chen & Fayerweather (1988); Fayerweather et al. (1992), USA
- Fryzek *et al.* (2003), USA
- Boffetta et al. (2004), 6 EU countries

«*All the studies had methodological limitations*. ...None of the studies was designed to assess the impact of particle size (fine or ultrafine) or the potential effect of the coating compounds on the risk for lung cancer."



IARC Monographs on the Evaluation of Carcinogenic Risks to Humans


VOLUME 93 Carbon Black, Titanium Dioxide, and Talc



And what happened since ?

In the USA, NIOSH Current Intelligence Bulletin (April 2011)

- Quantitative risk assessments for fine and ultrafine TiO₂
 - Hazard identification in humans



And what happened since ?

In the USA, NIOSH Current Intelligence Bulletin (April 2011)

- Quantitative risk assessments
 - Dose-response data in rats: HUMAN lung cancer and RECOMMENDED EXPOSURE LIMIT pulmonary inflammation Technical feasibility RAT Variability/uncertainty Dose-response model WORKING LIFETIME (PARTICLE SURFACE AREA EXPOSURE CONCENTRATION^{*} DOSE IN LUNGS) Human lung dosimetry model Extrapolate **CALCULATE TISSUE** EQUIVALENT TISSUE DOSE (species DOSE-BMD differences in lung surface area) Assume equal response to equivalent dose

*Compare rat-based risk estimates with upper bound on risk from human studies NIOSH recommends exposure limits of 2.4 mg/m³ for fine TiO_2 and 0.3 mg/m³ for ultrafine (including engineered nanoscale) TiO_2 , as time-weighted average (TWA) concentrations for up to 10 hours per day during a 40-hour work week. NIOSH has determined that <u>ultrafine TiO_3</u> is a potential occupational carcinogen but that there are insufficient data at this time to classify fine TiO_2 as a potential occupational carcinogen. However, as a precautionary step, NIOSH used all of the animal tumor response data when conducting dose-response modeling and determining separate RELs for ultrafine and fine TiO_2 . These recommendations represent levels that over a working lifetime are estimated to reduce risks of lung cancer to below 1 in 1,000. NIOSH realizes that knowledge about the health effects of nanomaterials is an evolving area of science. Therefore, NIOSH intends to continue dialogue with the scientific community and will consider any comments about nano-size titanium dioxide for future updates of this document. (Send comments to nioshdocket@cdc.gov.)

NIOSH urges employers to disseminate this information to workers and customers and requests that professional and trade associations and labor organizations inform their members about the hazards of occupational exposure to respirable TiO₂.



www.osha.gov (800) 321-OSHA (6742)

DTSEM FS-3634 04/2013

elligence Bulletin (April 2011)



Senartine of the Construction of Construction

And what happened since ?

In the EU

TiO2 = poorly soluble, low-toxicity particles





REACH Regulation aims to improve the protection of human health and the environment from the risks that can be posed by chemicals.



The **CLP** Regulation ensures that the hazards presented by chemicals are clearly communicated to workers and consumers in the EU through classification and labelling of chemicals.




The Chemical Agents Directive (CAD) and the Carcinogens and Mutagens Directive (CMD) provide a framework for setting occupational exposure limits, forming an integral part of the EU's mechanism for protecting the health of workers.



EU CLP Regulation (*Classification, Labelling and Packaging of chemicals*)


- The identified hazards must be communicated to other actors in the supply chain, including consumers (via a label and a safety data sheet)
- The objective is to alert stakeholders to the presence of a danger and the need to manage the associated risks
- The CLP classification affects other EU laws such as the Workers Directive (CMD 2004/37 / EC), which sets binding OELs and BLVs
- Revision in the frame of the CLH procedure

CLH procedure for CLP regulation revision



Approach followed by France (ANSES) for TiO2

- Systematic review of TiO2 production worker cohorts
- Critical assessment of bias using the OHAT method and gradation of the level of evidence



ANSES = The French Agency for Food, Environmental and Occupational Health & Safety

Mortality among workers employed in the titanium dioxide production industry in Europe*

Paolo Boffetta^{1,2,3}, Anne Soutar⁴, John W. Cherrie^{4,5}, Fredrik Granath², Aage Andersen⁶, Ahti Anttila⁷, Maria Blettner⁸, Valerie Gaborieau¹, Stefanie J. Klug⁸, Sverre Langard⁹, Daniele Luce¹⁰, Franco Merletti¹¹, Brian Miller⁴, Dario Mirabelli¹¹. Eero Pukkala⁷. Hans-Olov Adami¹ & Elisabete Weiderbass^{1,2,*}

Abstract

Objectives: To assess the risk of lung cancer mortality related to occupational exposure to titanium dioxide (TiO₂). *Methods*: A mortality follow-up study of 15,017 workers (14,331 men) employed in 11 factories producing TiO₂ in Europe. Exposure to TiO₂ dust was reconstructed for each occupational title; exposure estimates were linked with the occupational history. Observed mortality was compared with national rates, and internal comparisons were based on multivariate Cox regression analysis.

Results: The cohort contributed 371,067 person-years of observation (3.3% were lost to follow-up and 0.7% emigrated). 2652 cohort members died during the follow-up, yielding standardized mortality ratios (SMRs) of 0.87 (95% confidence interval [CI] 0.83–0.90) among men and 0.58 (95% CI 0.40–0.82) among women. Among men, the SMR of lung cancer was significantly increased (1.23, 95% CI 1.10–1.38) however, mortality from lung cancer did not increase with duration of employment or estimated cumulative exposure to TiO₂ dust. Data on smoking were available for over one third of cohort members. In three countries, the prevalence of smokers was higher among cohort members compared to the national populations.

Conclusions: The results of the study do not suggest a carcinogenic effect of TiO₂ dust on the human lung.

Key words: titanium dioxide, mortality, lung cancer, occupation.

Mortality among workers employed in the titanium dioxide production industry in Europe*

Paolo Boffetta^{1,2,3}, Anne Soutar⁴, John W. Cherrie^{4,5}, Fredrik Granath², Aage Andersen⁶, Ahti Anttila⁷, Maria Blettner⁸, Valerie Gaborieau¹, Stefanie J. Klug⁸, Sverre Langard⁹, Daniele Luce¹⁰, Franco Merletti¹¹, Brian Miller⁴, Dario Mirabelli¹¹. Eero Pukkala⁷. Hans-Olov Adami¹ & Elisabete Weiderbass^{1,2,*}

Cause of death		Country					
		Finland	France	Germany ^a	Italy	Norway	UK
All causes	Obs/Exp	224/276.1	305/313.8	1015/1131.7	89/99.8	84/96.0	902/1102.4
	SMR	0.81	0.97	0.90	0.89	0.87	0.82
	95% CI	0.71–0.92	0.87–1.09	0.84-0.95	0.72–1.10	0.70–1.08	0.77-0.87
All malignant neoplasms	Obs/Exp	34/51.2	125/103.3	319.5/298.3	28/37.1	21/23.6	279/312.9
	SMR	0.66	1.21	1.07	0.75	0.89	0.89
	95% CI	0.46–0.93	1.01–1.44	0.96–1.20	0.50–1.09	0.55–1.36	0.79–1.00
Lung cancer	Obs/Exp	12/15.8	36/25.4	128.5/84.8 💭	12/12.4	4/5.0	114/104.7
	SMR	0.76	1.42	1.51	0.97	0.79	1.09
	95% CI	0.39–1.32	0.99–1.96	1.26–1.79	0.50–1.69	0.21–2.02	0.90–1.31

Table 4. Standardized mortality ratios of selected causes by country

SMR, standardized mortality ratio; CI, confidence interval.

^a Observed deaths are not integer values (except for all causes of death) because of correction factors for missing causes of deaths.

Years of employment		Years since fi	rst employment			
		1-10	10.01-20	20.01-30	30.01+	Total
1–5	Obs/Exp	7.0/7.1	12.1/9.7	40.9/16.6	17.8/15	77.7/48.4
	SMR	0.99	1.24	2.47	1.19	1.61
	95% CI	0.4–2.03	0.64–2.15	1.78–3.36	0.71–1.90	1.27–2.01
5.01-10	Obs/Exp	9.0/9.2	10.1/7.7	11.2/9.7	3.2/7.2	33.5/33.7
	SMR	0.98	1.31	1.15	0.44	0.99
	95% CI	0.45–1.86	0.62–2.4	0.57–2.03	0.09–1.22	0.67–1.37
10.01–15	Hea	althy w	orker s (HWS	urvivor E)	effect	34.4/35.1 0.98 0.67–1.35 45.4/38.3
	95% CI		0.4/-1.51	0.85-2.11	0.64-2.30	1.18 0.85–1.56
20.01+	Obs/Exp			38.8/34.7	76.7/57.8	115.5/92.5
	SMR			1.12	1.33	1.25
	95% CI			0.80–1.54	1.05–1.67	1.03–1.49
Total	Obs/Exp	16.0/16.3	53.2/50.9	120.6/88.0	116.6/93.9	306.5/248.3
	SMR	0.98	1.05	1.37	1.25	1.23
	95% CI	0.56–1.59	0.78–1.37	1.14–1.64	1.04-1.50	1.10–1.38

Table 5. Standardized mortality ratios of lung cancer by duration of employment and time since first employment

SMR, standardized mortality ratio; CI, confidence interval.

^a Observed deaths are not integer values because of correction factors for missing causes of deaths.

Mortality among workers employed in the titanium dioxide production industry in Europe*

Paolo Boffetta^{1,2,3}, Anne Soutar⁴, John W. Cherrie^{4,5}, Fredrik Granath², Aage Andersen⁶, Ahti Anttila⁷, Maria Blettner⁸, Valerie Gaborieau¹, Stefanie J. Klug⁸, Sverre Langard⁹, Daniele Luce¹⁰, Franco Merletti¹¹, Brian Miller⁴, Dario Mirabelli¹¹. Eero Pukkala⁷. Hans-Olov Adami¹ & Elisabete Weiderbass^{1,2,*}

Table 6. Relative risk of mortality from lung cancer and nonmalignant respiratory diseases for estimated cumulative exposure to respirable TiO_2 dust

Cumulative exposure (mg/	S	elective	e reporting bias	5
Lung cancer				
0–0.73 0.73–3.43		Confli	ct of interest	
3.44-13.19	52	1.03	0.69-1.55	
13.20 +	53	0.89	0.58-1.35	
Linear trend, p-valu	e	0.5		
Non-malignant respiratory diseases				
0-0.8	40	1.00	Ref.	
0.9–3.8	39	1.23	0.76-1.99	
3.9-16.1	40	0.91	0.56-1.49	
16.2+	39	1.12	0.67-1.86	
Linear trend, p-valu	e	0.6		

Results of Cox regression analysis.

CLP Expertise conclusion

- Given the methodological bias in dose-response assessment and a statistically significant increase in lung cancer mortality reported in two publications, France has established that human data are not sufficient to conclude that there is no carcinogenic effect in humans and cannot contradict the carcinogenic effects observed in rats
- Need to re-analyze existing data and / or a meta-analysis

ECHA RAC decision

- Classification as a category 2 carcinogen (suspected human carcinogen) by inhalation for TiO2 in all its forms
- Inclusion in Annex VI of the CLP Regulation

And then...

Industrial repost

Country

Belgium

Date

15.07.2016

by France.

Comment received

Cerame-Unie, the Europe

including bricks & roof tile

table & decorative ware, t

accounts for more than 20

No cases of pulmonary fib

of Dupont "Epidemiologic

Dec;30(12):937-42 gave

TiO2 as a carcinogen cat.

the classification, which w

ANNEX 2 - COMMENTS AND RESPONSE TO COMMENTS ON CLH PROPOSAL ON TITANIUM DIOXIDE

COMMENTS AND RESPONSE TO COMMENTS ON CLH: PROPOSAL AND JUSTIFICATION

	Date Country		Organisation	Type of Organisation		Comment number		
oost	15.07.2016	Belgium	EuPC (European Plastics Converters	BehalfOfAnOrg	ganisation	5		
	Comment re	ceived						
Organisation	Type of Or	ganisation	Comment Digment, brightener or opacifier in most plastics stability important for outdoor applications.					
Date Country	Organ	isation						
15.07.2016 United Kingdom		BehalfOfAnOrganisatio		17	gnitude the whole € including polymer			
Dioxide is an important of material were to be class over fifty years and durin control and we are unaway exposure to TiO2 in the w wallpaper as containing a products due to misplace hazard is very low. Substitution of TiO2 for of products at a time when pressures. This proposed Europe	sed as a carcing this time ware of any he workplace. The carcinogen ad concerns a other materia the whole of	inogen. We have we have followed ealth issues expen- ne prospect that will potentially c about a hazard w ils would not be Europe does no	used TiO2 within our pr all statutory requirement erienced by our employed we may have to label out ause customers to stop then the potential for exp economic and will raise to t need any further inflation	oducts for nts for dust es through ur rolls of buying our posure to that the cost of onary		Commen number 10 taining more eans almost or not.		

https://echa.europa.eu/documents/10162/13626/clh_comments_titanium_dioxide_en.pdf

ACHA RAC response

Attachment to the responses to comments on the CLH repo

received during public consultation

514 comments have been received as a result of the public consult from 5 Member-States (Germany, Sweden, Finland, Netherlan individuals and the remaining from organizations. Among them:

- 176 are related to identity and scope of the dossier (in pa matrix),
- 338 are related to carcinogenicity (human and/or animal da
- 67 are related to hazard endpoints other than carcinogenicit
- 226 are related to exposure and risk assessment,
- 294 are related to economic impact of the proposed classifi

RAC response to comments on carcinogenicity (human data)

RAC independently assessed all the epidemiological studies available up to now, including four studies initially not assessed by DS, but mentioned during PC (Ellis et al., 2010, Ellis et al., 2013, Hext et al., 2005 and Thompson et al., 2016). RAC agreed with the general assessment made by Thompson et al. that epidemiological data support a moderate level of confidence for the human evidence and therefore can be used for carcinogenicity risk evaluation. RAC considers that human data do not consistently suggest an association between occupational exposure to TiO2 and risk for lung cancer as far as no specific TiO2 micro and nano particle sizes and/or specific physical forms are regarded. However, one cohort study by Boffetta et al. (2004) deals specifically with the respirable fraction of TiO2 dust (calculated from total dust) and suggests that there is no clear dose - response relationship expressed as RR for lung cancer; generally we do not have sufficient amount of relevant studies. In addition, Boffetta et al. (2004) indicated in their paper and Hext et al. (2005) repeated in their summary paper that the investigated TiO2 concentrations in the occupational environment generally could be too low to cause lung cancer. Therefore RAC

concludes that the animal carcinogenicity studies cannot be overruled.

And finally...

https://echa.europa.eu/fr/substance-information/-/substanceinfo/100.033.327 Titanium dioxide

ubstance identity	(?)	Hazard classification & labelling	(?)	Properties of concern	(?
C / List no.: 236-67	5-5			C Suspected to be Carcinoo	aenic
AS no.: 13463-67-7					-
Iol. formula: O2Ti		Warning! According to the harmonised classification			
		labelling (ATP14) approved by the European Union,	this substance is		
		suspected of causing cancer.		Nanomaterial form	(?
		EU classification of CMR substant	ces	Substance is known to market in nanomateria	
Category		Criteria	а		i ioiiii.
Cat. 1 A	known to have CMR pot	ential for humans, based largely on human evidence			
	procurred to have CMD	potential for humans, based largely on experimental animal data		Important to know	?
Cat. 1 B	presumed to have Clink	potential for numaris, based largery on experimental animal data			

Re-analysis of the French data from Boffetta et al (2004)

Type of TiO2 exposure variable	Observed lung cancer		/Iodel 1*	N	fodel 2*		Model 3*
Binary exposed Vs non-exposed	14	3.75	[0.79-17.9]	4.34	[0.85-22.15]	3.77	[0.79-17.95]
Categorical annual average exposure Vs non-exposed							
$]0-0.3] mg/m^3$	7	4.04	[0.79-20.63]	5.94	[1.07-32.99]	4.15	[0.81-21.21]
$[0.3-2.4] \text{ mg/m}^3$	3	1.68	[0.26-10.93]	1.64	[0.24-11.11]	1.64	[0.25-10.67]
$>2.4 \text{ mg/m}^3$	4	28.28	[4.57-175.15]	12.97	[1.86-90.74]	27.33	[4.35-171.84]
Continuous annual average exposure (mg/m3)	16	2.10	[1.37-3.22]	1.70	[1.03-2.79]	2.07	[1.34-3.20]
Continuous cumulative exposure (mg/m3-year), 0 lag	16	1.02	[0.97-1.06]	-	-	1.02	[0.97-1.06]**
5-year lag	9	1.02	[0.98-1.07]	-	-	1.02	[0.98-1.07]**
10-year lag	5	1.03	[0.99-1.08]	_	-	1.03	[0.98-1.08]**
15-year lag	1	1.04	[0.98-1.11]	-	-	1.04	[0.98-1.11]**

Hazard ratios and associated 95%-confidence intervals are adjusted for calendar period in Model 1; for calendar period and exposure duration in Model 2; for calendar period, exposure duration and smoking status in Model 3, except for cumulative exposure variable ** adjusted only for calendar period and smoking status in Model 3

Guseva Canu I et al. Lung cancer mortality in the French cohort of titanium dioxide workers: some aetiological insights. Occup Environ Med 2020;**77**:795–7 Tomenson JA. Letter commentary on: lung cancer mortality in the French cohort of titanium dioxide workers: some aetiological insights. Occup Environ Med 2021;**78** Guseva Canu I et al. Letter: Response to Tomenson's letter on 'Lung cancer mortality in the French cohort of titanium dioxide workers: some aetiological insights. Some aetiological insights' Occup Environ Med 2021;**78**

Re-analysis of the EU data

International Agency for Research on Cancer



Research Project

<u>**Rea</u>na<u>ly</u>sis of <u>Ti</u>O2 human data (<u>RealyTi**</u>)</u>

As part of the CLP classification dossier on titanium dioxide, the available epidemiological data were evaluated (ANSES, 2017). Three occupational cohorts were identified: two American cohorts (Ellis et al., 2013, Fryzek et al., 2003) and a

Main conclusions

- Association between cumulative exposure and lung cancer mortality, after correction of the HWSE
- Exposure reduction corresponds to a significant reduction in the number of lung cancer deaths
- The safety of NIOSH REL (2.4 mg / m3) seems questionable

Essential Public Health Operations

- EPHO3: Health protection (environmental, occupational, food safety etc.)
- EPHO10: Advancing public health research to inform policy & practice

Statistiques


La population active suisse est championne en Europe

A fin 2018, la population active (15-64 ans) participant au marché du travail en Suisse a augmenté à 84,2%, contre 81,3% en 2010, juste derrière l'Islande avec 88,7%.

https://www.24heures.ch/economie/population-active-suissechampionne-europe/story/10701185

Essential Public Health Operations

- EPHO3: Health protection (environmental, occupational, food safety etc.)
- EPHO10: Advancing public health research to inform policy & practice





unisantė

Centre universitaire de médecine générale et santé publique · Lausanne



Thank you for your attention !

Prof. Guseva Canu

irina.guseva-canu@unisante.ch